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ABSTRACT
Hundreds of thousands of people are dying every year in the world from infections caused by drug resistant bacteria. Antibiotic 
resistance is a rapidly increasing problem mostly as a result of the worldwide overuse and misuse of antibiotics for conditions that 
do not require them. The rapid spread of antibiotic resistance in bacteria makes it necessary to intensify the development of new 
antibiotics and new methods to combat drug resistant bacteria. The goal of this publication is to review the approaches to finding 
new antibiotics that are active against drug resistant bacteria. The first part of this review is focused on an analysis of the mecha-
nisms of action of antibiotics that are used in clinical practice as well as the mechanisms of bacterial resistance. The molecular 
structure and modes of action of these antibiotics are reviewed with examples of detailed mechanisms of drugs interaction with 
the targets in bacteria. General and specific mechanisms of bacterial resistance to these antibiotics are described. Examples of new 
antibiotics development active against the drug resistant bacteria are presented. 
INTRODUCTION
Antibiotic resistance is the natural tendency for bacte-
ria to change under the process of natural selection in 
such a way that they survive when exposed to the action 
of previously potent antibiotics. Antibiotic resistance is 
a rapidly increasing problem, largely as a result of the 
worldwide misuse and overuse of antibiotics for condi-
tions that do not require them.
Hundreds of thousands of people are dying every year 
in the world from infections caused by antibiotic-resis-
tant bacteria [1]. In February 2017, the WHO published 
[2] a list of the most dangerous antibiotic-resistant bac-
teria  – ‘priority pathogens’ that includes 12 families 
(Table 1). The purpose of this publication was to raise 
awareness in the world’s scientific community in order to 
organize and guide the research and development efforts 
in academia and pharmaceutical industry focused on the 
search for new antimicrobial agents.
Microorganisms acquire antibiotic resistance through 
chromosomal DNA mutations and horizontal gene trans-
fer that eventually lead to a change of bacterial pro-
teins. There are several mechanisms of horizontal gene 
transfer in bacteria – transformation, transduction, and 
conjugation [3]. Multi-resistant bacteria or ‘superbugs’ 
have emerged recently due to the horizontal transfer of 
genetic material that has spread antibiotic resistance. 
Table 1. The most dangerous antibiotic-resistant bacteria
Priority Families
Critical 1. Acinetobacter baumannii, carbapenem-resistant
2. Pseudomonas aeruginosa, carbapenem-resistant
3. Enterobacteriaceae, carbapenem-resistant, 
β-lactamase producing
High 1. Enterococcus faecium, vancomycin-resistant
2. Staphylococcus aureus, methicillin-resistant, 
vancomycin-intermediate and resistant
3. Helicobacter pylori, clarithromycin-resistant
4. Campylobacter spp., fluoroquinolone-resistant
5. Salmonellae, fluoroquinolone-resistant
6. Neisseria gonorrhoeae, cephalosporin-resistant, 
fluoroquinolone-resistant
Medium 1. Streptococcus pneumoniae, penicillin-non-
susceptible
2. Haemophilus influenzae, ampicillin-resistant
3. Shigella spp., fluoroquinolone-resistant
Recently, scientists from Harvard Medical School (USA) 
and Technion – Israel Institute of Technology – have de-
signed an experiment visualizing how bacteria acquire 
resistance to antibiotics [4]. The most dangerous group 
of multidrug resistant bacteria include E. coli, Klebsiella, 
Acinetobacter, Serratia, Pseudomonas, Proteus and some 
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other bacteria that cause severe diseases such as blood-
stream bacteremia and pneumonia. These infections are 
easily spread in hospitals and nursing homes and often 
lead to a lethal outcome.
The goal of this publication is to introduce the chal-
lenging and exciting field of the design and discovery 
of new antibiotics to the wide community of medicinal 
chemists and scientists interested in drug discovery and 
development. 
The structure of bacteria and types of bacterial 
resistance to antibiotics
Bacteria being simple organisms contain a well-devel-
oped cell structure (Fig.  1). The cell wall provides the 
structural integrity to bacterial cell and, therefore, it is 
one of the most important components of the cell en-
velope. Both Gram-positive and Gram-negative bacteria 
contain an inner membrane in the form of a phospho-
lipid bilayer. Gram-negative bacteria also have the outer 
membrane. Gram-positive bacteria do not contain the 
outer membrane but the cell wall in this type of bacte-
ria is much thicker than that in Gram-negative bacteria. 
Both Gram-positive and Gram-negative bacteria have 
DNA, ribosomes and the corresponding enzymes for DNA 
replication, transcription and translation in order to pro-
duce the necessary proteins for the bacterial cell. All the 
main elements of the bacterial cell envelope as well as or-
ganelles and DNA, mRNA, and tRNA molecules and their 
complexes that are formed in the course of the protein 
synthesis can be the targets for antibiotics (Fig. 2). The 
main targets for antibiotics in bacteria are: a) interme-
diates in the cell wall biosynthesis, b) cell membrane, c) 
biomolecules and organelles involved in the processes of 
protein biosynthesis, d) bacterial DNA and RNA, and e) 
enzymes involved in the biosynthesis of tetrahydrofolate.
Fig. 1. Structure of Gram-positive bacteria (reprinted from [5]).
Bacteria use several mechanisms for protection from 
antibiotics that function as mechanisms of resistance. 
The most common mechanisms of resistance among bac-
teria are:
a) biosynthesis of enzymes in the bacterial cell that de-
activate antibiotics [7, 8].
b) active efflux of antibiotics from the bacterial cell that 
is accomplished by integral membrane transporters 
also known as efflux pumps or drug pumps [9, 10].
c) change in the structure of bacterial organelles or en-
zymes that are the antibiotic targets in order to pre-
vent or diminish the action of antibiotics [11, 12].
d) change in the structure of the intermediates involved 
in the process of bacterial cell wall synthesis prevent-
ing the disruption of this process by antibiotics [13].
e) change in the bacterial membrane leading to preven-
tion of antibiotic – membrane interaction [14, 15].
Fig. 2. The main antibiotic targets in bacteria and the main mecha-
nisms of bacterial resistance (reprinted from [6]).
Some scientists consider the formation of bacterial 
biofilms as one of the mechanisms of bacterial resistance, 
but bacterial biofilms will not be discussed in this review.
Since the efflux of antibiotics that is used by both 
Gram-positive and Gram-negative bacteria is a general 
mechanism of resistance to antibiotics that belong to dif-
ferent classes and have quite different molecular struc-
tures, it will be briefly discussed in this section. Active 
efflux is a method that bacteria use for transporting un-
wanted toxic compounds and antibiotics out of the cell. 
Efflux pumps are single proteins (Gram-positive bacte-
ria) or a combination of several proteins (Gram-negative 
bacteria) that are embedded in the bacterial membrane 
and function like transporters for chemical compounds. 
There are five distinct types of efflux pumps known to 
date: MFS (major facilitator class), RND (resistance-
nodulation-division), SMR (small multidrug resistance 
class), MATE (multidrug and toxin exclusion), and ABC 
(ATP-binding cassette). Since the pumping of antibiotics 
is accomplished often against the concentration gradient, 
this process requires energy. Most of the efflux pumps – 
MFS, RND, SMR, and MATE – are powered by the flow of 
the protons that decreases the proton gradient across the 
bacterial membrane. The ABC pumps use ATP (adenosine 
triphosphate) hydrolysis as the energy source. 
Mechanisms of action of known antibiotics 
and the modes of bacterial resistance to them
Natural, semi-synthetic and synthetic antibiotics are suc-
cessfully used today in clinical practice to fight bacterial 
infection. Following the generally accepted classification 
based mostly on molecular structure [16] all marketed 
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antibiotics can be divided into several major classes: 
β-lactams, glycopeptides and lipoglycopeptides, sulfon-
amides, aminoglycosides, tetracyclines, macrolides, rifa-
mycines, fluoroquinolones, streptogramines, oxazolidi-
nones, and lipopeptides. An overview of the history of 
search for antibiotics is given in a paper by Mohr [17]. The 
mechanisms of action of drugs within each of these an-
tibiotic classes are similar. On the contrary, the mecha-
nisms of action of drugs from different antibiotic classes 
are significantly different. 
The antibiotics structure, mode of action, and mode 
of bacterial resistance to these antibiotics are presented 
below. The molecular mechanisms for these processes 
are discussed.
a. β-Lactams
One of the most widely used classes of antibiotics is 
β-Lactams (e.g. Fig. 3).
The first antibiotic penicillin was isolated from Peni-
cillium fungi by Alexander Fleming in 1928 [18].
Penicillin belongs to the β-lactam family of antibio-
tics that have the distinctive structural fragment – four 
membered β-lactam ring. Cephalosporins (e.g. cefaclor, 
Fig. 3) also contain β-lactam cycle. The first member of 
this class of antibiotics – cephalosporin C – was isolated 
from Cephalosporium acremonium.
    
 A B
Fig. 3. Penicillin G (A) and cefaclor (B).
There are a number of semisynthetic antibiotics among 
β-lactams. 
Later attempts to find new β-lactam antibiotics led to 
the development of carbapenems (Fig. 4).
         
 
A B
Fig. 4. Meropenem (A) and doripenem (B).
β-Lactam antibiotics act by the inactivation of the 
transpeptidases that catalyze the last step in peptidogly-
can cross-linking. The main component of the cell wall 
that provides its structural integrity in both Gram-positive 
and Gram-negative bacteria is peptidoglycan – the cross-
linked peptide-sugar copolymer. The cross-linking of the 
glycan polymer chains that makes the cell wall strong and 
rigid is accomplished by the formation of peptide strands 
that connect the glycan chains. The linking of two pep-
tide strands attached to different glycan chains is the last 
step in the bacterial cell wall synthesis. It is catalyzed by 
transpeptidases – enzymes that have serine at their ac-
tive sites. This enzyme attacks the D-alanyl-D-alanyl site 
of the first peptide strand and forms active acyl-enzyme 
intermediate with the simultaneous displacement of the 
terminal alanine (Fig. 5). Then, in Gram-negative bacte-
ria, the amino group of diaminopimelic acid of the second 
peptide strand reacts with the acyl-enzyme intermediate 
and the crosslinking reaction is finished by the formation 
of the peptide bond between the two peptide strands. In 
Gram-positive bacteria, where diaminopimelic acid in the 
second peptide strand is replaced by lysine, the connec-
tion with the first peptide strand is accomplished through 
the peptide bridge that can contain several amino acids. 
For example, in Staphylococcus aureus this peptide bridge 
contains five glycine amino acids. In this case, the amino 
group of the last glycine reacts with the acyl-enzyme in-
termediate to finish the cross-linking process. Penicillins 
as well as cephalosporins inhibit the enzyme transpepti-
dase by binding to the active center of enzyme that leads 
to the formation of the stable acyl enzyme intermediate. 
As a result of this process, the enzyme cannot catalyze the 
cross-linking of glycan chains and the process of bacterial 
wall formation is disrupted as shown in Figs. 6 and 7 [19].
Bacteria developed resistance to penicillin by the pro-
duction of enzymes β-lactamases [20, 21] and later to 
cephalosporin drugs by production of cephalosporinases 
(e.  g. class C β-lactamases) [21] and other β-lactamase 
enzymes known as extended-spectrum β-lactamases 
(ESBL) [22, 23]. These enzymes cleave the peptide bond 
in the β-lactam cycle of the corresponding penicillin 
molecule that leads to the loss of drug activity. (Fig. 8).
Fig. 5. Cross-linking step in the synthesis of peptidoglycan.
        
 A B
Fig. 6. D-alanyl-D-alanyl terminus of the peptide strand (A) and 
penicillin (B).
Fighting bacterial resistance
mir-journal.org 34  Volume 4    Number 1     2017
Fig. 7. Different products of transpeptidase reactions with D-ala-
nyl-D-alanyl fragment of the peptide strand and with β-lactam 
anti biotic.
Fig. 8. Deactivation of β-lactam antibiotics by enzyme β-lactamase.
The search for methods to overcome bacterial resis-
tance to penicillin antibiotics led to the discovery of a 
number of β-lactamase enzymes inhibitors like clavu-
lanic acid, sulbactam and tazobactam (Fig.  9) [24, 25]. 
Since that time, a number of penicillin antibiotics (e.g. 
ampicillin) were marketed by pharmaceutical companies 
as mixtures with the corresponding β-lactamase inhibi-
tors. Kuzin et al. [25] presented the X-ray crystallography 
data for the SHV-1 class A β-lactamase-tazobactam com-
plex and discussed the mechanism of this enzyme inhi-
bition by tazobactam. Mechanism of action of avibactam 
(Fig. 9), the effective inhibitor of class A, C and some class 
D β-lactamases and the first non-β-lactam β-lactamase 
inhibitor, is discussed in recent publications [26, 27].
The combination of tazobactam with the new antibi-
otic ceftolozane (Fig. 10) that belongs to the 5th genera-
tion of cephalosporins is marketed as Zerbaxa. This anti-
biotic shows high potency against several drug resistant 
strains [28, 29].
The strategies to discover new β-lactam antibiotics 
and the development of bacterial resistance to them are 
reviewed by Llarrull et al. [30]. Unfortunately, the known 
β-lactamase enzymes inhibitors that are active against 
class A, C, and D β-lactamases cannot deactivate class B 
metallo-β-lactamases. These enzymes, containing Zn in 
their active site, utilize a different mechanism to cleave 
the β-lactam cycle of antibiotics. Monobactams [31] 
(Fig. 11) are the only group of β-lactam antibiotics that 
can effectively inhibit those enzymes [32, 33]. Thus, the 
results published by Marshall et al. [34] suggest the com-
bination of ceftazidime-avibactam and aztreonam could 
be used to overcome resistance of bacteria producing 
metallo-β-lactamases.
In addition, known β-lactamase enzyme inhibitors 
are not active enough against the extended-spectrum 
cephalosporinases [35, 36]. Today, the search for the po-
tent inhibitors of this class of enzymes is an area of ac-
tive exploration [26, 37]. On the other hand, the search 
for the new types of β-lactamases inhibitors continues. 
Thus, Venugopal et al. [38] published interesting results 
on using peptidyl boronate analogues as broad-spectrum 
β-lactamase inhibitors. 
Another approach to combatting β-lactamase resis-
tance is to block one of the key steps in the biosynthesis 
         
 A B
         
 C D
Fig. 9. β-Lactamase enzymes inhibitors. Clavulanic acid (A), sul-
bactam (B), tazobactam (C), avibactam (D).
Fig. 10. Ceftolozane.
                 
 A B
Fig. 11. Aztreonam (A) and sulfazecin (B).
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of these enzymes that was demonstrated by Bouquet 
et al. for AmpC β-lactamase [39]. Recently discovered 
2-aminobenzimidazoles were found to significantly re-
duce the bacterial resistance to a number of β-lactam 
antibiotics [40]. It is believed that these compounds have 
a different mechanism of action from the β-lactamase 
inhibitors.
Expression by the bacteria of the mutant enzyme 
transpeptidase (mutant penicillin-binding protein – 
PBP2 enzyme) that has a reaction center practically in-
accessible to the β-lactam antibiotics but, on the other 
hand, perfectly capable of catalyzing the crosslinking 
reaction in the course of peptidoglycan synthesis, serves 
as another way of bacterial resistance to β-lactam anti-
biotics [41]. It was discovered that in order to catalyze 
the crosslinking of peptidoglycan the active center of 
the enzyme should undergo conformational change. 
This conformational change is probably triggered by the 
interaction of the corresponding peptidoglycan frag-
ments with the allosteric site of this enzyme [41]. Then, 
it was shown that some β-lactams like ceftaroline are 
able to interact with the allosteric site of the enzyme 
leading to the conformational change – opening of its 
active site – that enables the second molecule of cef-
taroline to react with the enzyme active site, thereby 
finishing the enzyme inactivation [41, 42]. Fishovitz 
et al. reported that the triggering of the allosteric cite of 
PBP2 enzyme by one β-lactam antibiotic enables anoth-
er β-lactam drug to interact with the active cite of that 
protein. Therefore, they report that there is synergy in 
the action of ceftaroline and some other β-lactams like 
oxacillin, imipenem, and meropenem against the MRSA 
bacterial strains [43]. 
Other mechanisms of antibiotic resistance in Gram-
negative bacteria involve structural and/or functional 
changes in porin superfamily transporters that are im-
bedded in the bacterial outer membrane. These changes 
strongly affect the rate of antibiotics permeation though 
the bacterial outer membrane. It was shown that muta-
tions of porins or switching to the expression of the other 
type porins with a different pore size or different electro-
static interactions in the porin eyelet region lead to a de-
crease in the permeability of β-lactams in Gram-negative 
bacteria that serves as the reason for bacterial resistance 
to these antibiotics [44, 45]. 
b. Glycopeptides and Lipoglycopeptides
Another class of antibiotics that act by preventing the 
biosynthesis of the bacterial cell wall is glycopeptides 
(e. g. Fig. 12) and their semisynthetic derivatives – lipo-
glycopeptides (e. g. Fig. 17).
Both vancomycin and teicoplanin are natural antibi-
otics produced by microorganisms. Vancomycin was iso-
lated from the soil bacteria Amycolatopsis orientalis. Tei-
coplanin is a mixture of natural antibiotics isolated from 
bacteria Actinoplanes teichomyceticus. Glycopeptides act 
as inhibitors of the peptidoglycan synthesis in bacterial 
cell wall. Vancomycin binds to the D-alanyl-D-alanyl end 
fragment in the peptide strands of the peptidoglycan in-
termediate and prevents the cross-linking of the peptide 
polymer chains (Fig. 13).
A
   
B
     
Teicoplanin core
    
R (side chain)
Fig. 12. Vancomycin (A) and teicoplanin (B). 1 – Teicoplanin A2-1; 
2 – teicoplanin A2-2; 3 – teicoplanin A2-3; 4 – teicoplanin A2-4; 
5 – teicoplanin A2-5.
The bacterial strains resistant to vancomycin emerged 
as a response to the action of this antibiotic. These new 
bacterial strains have cell walls with a different structure 
of peptide chains terminus – D-alanyl-D-lactate – in-
stead of D-alanyl-D-alanyl. Since vancomycin forms 5 
hydrogen bonds with a D-alanyl-D-alanyl fragment and 
only 4 hydrogen bonds with D-alanyl-D-lactate frag-
ment (Fig.  14) its activity decreases 1,000-fold against 
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increased potency against methicillin-resistant Staphy-
lococcus aureus and some vancomycin resistant strains.
An interesting approach to improve vancomycin ac-
tivity against resistant bacteria was used by Okano et al. 
[48]. They changed one functional group and introduced 
2 new functional groups in the molecule of vancomycin 
(Fig.  16). These new functional groups enable the new 
drug to act as an antibacterial agent according to two 
different mechanisms. As a result, the new vancomycin 
drug molecule has three possible different mechanisms 
of action and showed high activity against vancomycin-
resistant bacteria.
Kang et al. [49] showed that combinations of vanco-
mycin with non-β-lactam antibiotics like ciprofloxacin 
and gentamicin give a synergetic effect against bacteria 
with reduced susceptibility to vancomycin. Yarlagadda 
et al. [50] showed that lipophilic vancomycin aglycon di-
mer is 300  times more active compared to vancomycin 
against some vancomycin resistant bacteria. They also 
reported that vancomycin-sugar derivatives, especially 
lipophilic vancomycin-sugar analog, exhibit significantly 
higher activity against the vancomycin resistant strains 
than vancomycin itself [51].
In attempt to improve the activity of vancomy-
cin a number of its semisynthetic derivatives has been 
Fig. 13. Interaction of vancomycin with the D-alanyl-D-alanyl end 
fragment in peptide strand in the course of peptidoglycan synthesis.
Fig.  14. Interaction of vancomycin with D-alanyl-D-alanyl frag-
ment (X = NH, hydrogen bond is formed with vancomycin amide 
oxygen) or D-alanyl-D-lactate (X = O, no hydrogen bond) fragment 
of peptide strain.
Fig. 15. Interaction of vancomycin aglycon with D-alanyl-D-alanyl 
(X = NH) or D-alanyl-D-lactate (X = O).
Fig. 16. Structure of improved vancomycin [48].
these vancomycin-resistant bacteria. Xie et al. [46] re-
ported the synthesis of vancomycin aglycon (Fig. 15) spe-
cially designed to interact with both D-alanyl-D-alanyl 
and modified D-alanyl-D-lactate fragments in peptide 
strands. This compound showed high potency against 
vancomycin-resistant bacteria. 
Silverman et al. [47] described the synthesis of van-
comycin dimers and showed that these compounds have 
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isolated and studied [52]. As a result of these research 
efforts, three new drugs – dalbavancin, telavancin and 
oritavancin, that belong to the subclass of lipoglyco-
peptides (Fig. 17) - were introduced to the market. They 
have certain advantages as compared with vancomycin. 
Dalbavancin requires fewer frequent dosing because it 
has much longer half-life. The lipophilic fragments in 
the structures of both telavancin and oritavancin enable 
these drugs to have a second mechanism of action – to 
induce the membrane depolarization in bacterial cell. 
Due to this dual-action mechanism, both antibiotics 
show excellent antibacterial activity. Telavancin also has 
significantly improved ADME (adsorption, distribution, 
metabolism and excretion) profile [52, 53]. 
c. Sulfonamides
Sulfonamides represent another important class of anti-
biotics that inhibit the synthesis of the folic acid metab-
olite - tetrahydrofolate. This compound is an important 
intermediate in different biosynthetic reactions and also 
plays an important part in the cell division process. Sul-
fanilamide and sulfamethoxazole are the main examples 
of sulfonamides (Fig. 18). Sulfanilamide is a synthetic an-
tibiotic the structure of which is close to that of p-Ami-
nobenzoic acid (PABA) (Fig. 19).
        
 A B
Fig. 18. Sulfanilamide (A) and sulfamethoxazole (B).
         
 A B
Fig. 19. Sulfanilamide (A) and p-aminobenzoic acid (PABA) (B).
Sulfonamide antibiotics mimic p-aminobenzoic acid 
in the process of tetrahydrofolate synthesis (Fig. 20) and 
are potent against both Gram-negative and Gram-posi-
tive bacteria. By interacting with enzyme Dihydroptero-
ate Synthase (DHPS) this class of antibiotics prevents 
the formation of intermediate I in the synthesis of tetra-
hydrofolate (Fig. 20) [54, 55]. 
Fig. 20. Synthesis of tetrahydrofolate.
A
   
B
   
C
   
Fig.  17.  Lipoglycopeptide antibiotics: A – dalbavancin, B – tela-
vancin, C – oritavancin.
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Resistance to sulfonamide antibiotics developed be-
cause the small fraction of bacteria can use very small 
concentrations of folic acid provided by the host organ-
ism. Since bacteria reproduce fast, even a small number 
of surviving bacterial cells results in the spread of infec-
tious disease in humans. Another mechanism of bacterial 
resistance to sulfonamides [56] involves certain muta-
tions in enzyme DHPS that make it practically insensi-
tive to these drugs. At the same time, the mutant enzyme 
preserves the ability to bind the PABA that is structurally 
very similar to sulfonamides.
Search for the inhibitors of the enzyme dihydrofolate 
reductase (DHFR) that catalyzes the conversion of dihydro-
folic acid into tetrahydrofolate, led to the discovery of di-
aminopyrimidines – the second class of synthetic drugs 
that disrupt the tetrahydrofolate synthesis in bacteria. 
These compounds (e.g. trimethoprim, Fig.  21) prevent 
the reduction step in the synthesis of tetrahydrofolate. 
Fig. 21. Trimethoprim.
Trimethoprim inhibits the reduction of dihydrofolic 
acid to tetrahydrofolic acid by binding to the enzyme di-
hydrofolate reductase (DHFR). Therefore, the combina-
tion of sulfonamide antibiotics with diaminopyrimidines 
was successfully used in fighting both Gram-positive and 
Gram-negative bacteria. Resistance to trimethoprim in 
some pathogenic bacteria developed as a result of the 
single amino acid Ile100Leu substitution in dihydrofo-
late reductase (DHFR) [57]. Recently, Nepka et al. [58] 
showed that the combination of sulfamethoxazole-trim-
ethoprim with colistin could be effectively used for fight-
ing carbapenem-resistant bacterial strains. Bavadi et al. 
describe the synthesis of the series of new dihydropyr-
rol-2-one compounds containing sulfonamide groups. 
Most of these compounds showed antibacterial activity 
against P.  aeruginosa and S.  epidermidis and were more 
active against the P. aeruginosa than the combination of 
trimethoprim-sulfamethoxazole [59]. 
d. Aminoglycosides
Another group of antibiotics (streptogramins, macro-
lides, oxazolidinones, tetracyclines and aminoglyco-
sides) kills bacteria by disrupting its protein synthesis. 
The targets for these drugs are both large 50S and small 
30S ribosomal subunits. One of the antibiotic classes that 
target the bacterial ribosome is aminoglycosides (e.g. 
streptomycin and kanamycin Fig. 22).
Aminoglycosides are natural antibiotics. Streptomy-
cin – the first member of this class of antibiotics – was 
isolated from the Gram-positive bacteria Streptomyces 
griseus. Streptomycin inhibits the protein synthesis in 
bacteria by binding to the 30S subunit of the bacterial ri-
bosome. That leads to codon misreading over the course 
of the translation process, resulting in the synthesis of 
proteins with wrong structures and eventually to bacte-
rial death. Interaction of neomycin with 50S ribosomal 
subunit is shown below (Fig. 23) [60].
Streptomycin-resistant bacterial strains (both Gram-
positive and Gram-negative) emerged after the intro-
duction of this antibiotic and its analogues. Action of 
several bacterial enzymes such as acetylase, adenylase, 
and phosphorylase leads to the deactivation of amino-
glycoside antibiotics [7, 8] (Fig. 24). Enzymatic acetyla-
tion, phosphorylation, and adenylylation produce modi-
fied drug molecules that have lost their antibacterial 
activity. 
In order to overcome bacterial resistance, new semi-
synthetic aminoglycoside antibiotic amikacin (Fig.  25) 
was designed. This compound is stable to enzymatic de-
activation. The amikacin binds to the A-site of 16S rRNA 
that disrupts the protein synthesis.
In this molecule, the L-hydroxyaminobutyramide 
moiety attached to the central ring fragment protects the 
drug from attacks by certain bacterial antibiotic inacti-
vating enzymes. Another semisynthetic drug candidate 
that is stable to enzymatic acylation, phosphorylation, 
and adenylylation – plazomicin (Fig. 26) – is now in the 
development stage.
A
    
B
    
 Fig. 22. Streptomycin (A) and kanamycin A (B).
Fig. 23. Interaction of neomycin with 50S ribosomal subunit.
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bacterial cell (an example: tigecycline, Fig. 28) [62] and 
disrupt the translation (synthesis of proteins) process by 
preventing aminoacyl-tRNA from binding to the corre-
sponding site of mRNA – ribosome complex.
Since this class of antibiotics was used extensively, the 
bacterial resistance emerged without delay. Three ma-
jor mechanisms of resistance to tetracyclines have been 
recognized to date: efflux of the drug molecules from the 
bacterial cell by the efflux pumps, enzymatic modification 
of tetracycline molecule leading to its inactivation and ri-
bosomal protection [63]. The latter involve the synthesis 
of ribosomal protection proteins (RPPs) (e.g. Tet(O) and 
Tet(M)) that significantly reduce the binding of tetracy-
cline antibiotics to the ribosome subunit or displace them 
from the binding site. Ribosomal protection is considered 
to be one of the two major mechanisms of bacterial resis-
tance against tetracyclines [64]. This approach is used by 
both Gram-positive and Gram-negative bacteria. 
One of the efficient ways to fight the drug resistant 
strains of bacteria is the chemical modification of exist-
ing antibiotics. By using this approach, new representa-
tives of this class of drugs efficient against the resistant 
strains were discovered [65, 66] (Fig. 29). 
Another major mechanism of tetracyclines resistance 
in bacteria is drug efflux from bacterial cell. It was proven 
that membrane-associated proteins (e.g. Tet(A), Tet(B), 
Tet(C)) are responsible for the efflux of tetracyclines 
from bacteria [63]. Most of them belong to the major 
Adenosine monophosphate (AMP)
Fig.  24.  Enzymatic deactivation of aminoglycoside antibiotics. 




Another class of broad-spectrum antibiotics that target 
the 30S ribosomal subunit is tetracyclines (Fig. 27).
Tetracyclines are natural products. The first member 
of this class of antibiotics – chlorotetracycline – was iso-
lated from the bacteria Streptomyces aureofaciens. There 
are also a number of semisynthetic tetracycline drugs. In 
the review by Liu et al. practical methods of the synthesis 
of tetracyclines are summarized including an example of 
the successful synthesis of a new potent antibiotic erava-
cycline that is currently in clinical trials [61]. 
Tetracyclines are broad-spectrum antibiotics active 
against both Gram-negative and Gram-positive bacteria. 




   
Fig. 27. Chlorotetracycline (A) and oxytetracycline (B).
Fig. 28. Mg-tigecycline complex interactions with residues of 16S 
rRNA (30S ribosome subunit).
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f. Streptogramins
One of the antibiotic classes that target the large 50S 
ribosomal subunit is streptogramins (e.g. dalfopristin 
(streptogramin A) and quinupristin (streptogramin B), 
Fig. 32).
A
     
B   
  
Fig. 32. Dalfopristin(A) and quinupristin(B).
Both dalfopristin and quinupristin are semisynthetic 
modifications of the natural streptogramin antibiot-
ics produced by various Streptomyces bacteria. Strep-
togramins inhibit the bacterial protein synthesis by 
binding to the 50S ribosomal subunit. Group A strepto-
gramins (dalfopristin) bind in the peptidyltransferase 
center (PTC) and interfere with binding of aminoacyl-
tRNAs, which prevents the formation of a peptide bond 
during the elongation step. Streptogramin B components 
(quinupristin) bind to the proximal end of the exit tun-
nel resulting in the release of the small incomplete oligo-
peptide chains [73, 74]. Each compound shows moderate 
activity, whereas the combination of both drugs demon-
strates a synergetic effect. The binding of dalfopristin 
results in a specific conformational change of the 50S ri-
bosomal subunit that significantly facilitates the conse-
quent binding of quinupristin. As a result, administration 
of the dalfopristin and quinupristin mixture (marketed as 
Synercid) produces much higher antibacterial activity.
Bacteria have developed several mechanisms of resis-
tance to these antibiotics including active efflux from the 
bacterial cell, 23S rRNA methylation, and enzymatic de-
activation. The acetylation of the OH group in dalfopris-
tin and its analogues catalyzed by O-acetyltransferases 
(e.g. virginiamycin acetyltransferase) results in the for-
mation of O-acetyl products that do not have the bind-
ing affinity to 50S ribosome subunit [73]. Enzymatic de-
activation of quinupristin and its structural homologues 
proceeds by lactone opening catalyzed by virginiamycin 
B lyase (Vgb) resulting in the formation of linear prod-





Fig. 29. Tigecycline (A) and pentacycline (B).
Fig. 30. Cyclopentylthiotetracycline (13-CPTC).
Fig. 31. Fluorocycline TP-271.
facilitator superfamily (MFS) of efflux transporters [9, 
10, 67] though some of them (e.g. EfrAB [9, 68]) belong to 
the ATP-binding cassette (ABC) family of efflux pumps. 
Thus, Tet proteins transport tetracycline molecules coor-
dinated with the divalent cations (Ca2+ or Mg2+) through 
the bacterial membrane in exchange for the protons [67, 
10]. Nelson et al. [69] demonstrated that cyclopentylthio-
tetracycline (13-CPTC) is an efficient inhibitor of Tet(B) 
protein. The uptake of tetracycline into the resistant 
bacteria was significantly increased in the presence of 
13-CPTC (Fig.  30) as a result of bacterial efflux pumps 
blockage. Therefore, the simultaneous administration of 
13-CPTC with tetracycline can restore the activity of this 
antibiotic against the resistant bacteria.
A new antibiotic fluorocycline TP-271 (Fig.  31), de-
scribed recently by Grossman et al. [70], demonstrates 
high in vitro potency against multidrug-resistant bac-
teria. These results once more show that changing the 
antibiotic’s structure is a promising approach to combat 
bacterial resistance. 
The third – less prevalent – mechanism of resistance 
is the chemical modification of tetracyclines studied by 
Speer et al. [71]. They found that tetracycline is chemical-
ly modified in bacteria that carry the *Tcr gene in aerobic 
conditions. The structures of modified tetracycline prod-
ucts were not determined. The impact of tetracyclines 
coordination with metals on antimicrobial activity was 
reviewed by Guerra et al. [72].
 Volume 4   Number 1     2017 41 mir-journal.org 
Fighting bacterial resistance
This development accelerated the search for new strep-
togramins active against the resistant strains. The main 
efforts to modify the structure of type A streptogramins 
were concentrated on the introduction of different sub-
stituents R in position 16 of 16-desoxopristinamycin II 
(Fig. 33). On the other hand, the substitution of the 4-oxo-
2-piperidinecarboxylic acid fragment in pristinamycin I 
(Fig. 33) by other heterocyclic amino acids led to the dis-
covery of several new active compounds [73]. An interest-
ing approach to the modification of the streptogramin 
structure was demonstrated by Mukhtar et al. [76]. Using 
synthetic and enzymatic methods, they prepared a series 
of chimeric compounds containing structural elements of 
streptogramins B and antibiotic tyrocidine. These com-
pounds showed a broad range of activity against Gram-
positive bacteria. It is believed that their mechanism of 
action is different from that of the parent antibiotics. 
A
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Fig. 33. 16-Desoxopristinamycin II (A) and pristinamycin I (B).
In a recent publication by Li et al., a new practical scal-
able approach to the synthesis of streptogramin antibiot-
ics is described. This method can lead to the discovery of 
new potent drugs that will overcome the limitations of 
known streptogramins [77]. 
g. Macrolides
Another class of antibiotics that target the large ri-
bosomal subunit is macrolides (e.g. azithromycin and 
erythromycin, Fig. 34).
    
 A B
Fig. 34. Azithromycin (A) and erythromycin (B).
Erythromycin is a natural compound isolated from the 
bacteria Saccharopolyspora erythraea. Azithromycin is one 
of semisynthetic analogues of erythromycin. Erythromy-
cin binds close to the peptidyl transferase center (PTC) in 
the 50S ribosomal subunit at the end of the polypeptide 
exit tunnel. It affects the polypeptide chain elongation 
step and consequently disrupts the whole process of pro-
tein biosynthesis [78]. The mechanism of action of these 
antibiotics is discussed by Gaynor et al. [79].
During last two decades, we witnessed the emergence 
of bacterial resistance to macrolides and particularly 
to erythromycin [80]. There are three known mecha-
nisms of resistance. The primary mechanism involves 
post-transcriptional methylation of the 23S ribosomal 
RNA that prevents the antibiotic from binding to bacte-
rial ribosome [79]. The other mechanism of resistance is 
based on the action of efflux pumps that exert antibiotics 
from the bacterial cell [81]. One more possible mecha-
nism involves the ribosomal synthesis of small peptides 
(4-6  amino acids) that interact with the drug molecule 
bound to the 50S subunit of the ribosome and promote 
its release from the active site [79]. In order to fight bac-
terial resistance, the second (clarithromycin) and then 
the third (telithromycin) generation of macrolides were 
developed (Fig.  35). The latter has a significantly im-
proved affinity to both the native and mutant 50S ribo-
some subunits, although the new mutations that lead to 
this antibiotic resistance have already been reported [81].
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Fig. 35. Clarithromycin (A) and telithromycin (B).
Summary of practical methods of synthesis of new 
macrolide antibiotics is presented by Seiple et al. [82].
h. Oxazolidinones
Oxazolidinones (e.g. linezolid and tedizolid, Fig. 36) are 
the only completely synthetic class of antibiotics that 
target bacterial ribosome. 
The distinctive structural fragment of this class of an-
tibiotics is the five-membered oxazolidinone ring. This 
class of compounds was first investigated at DuPont and 
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then at Pharmacia [73]. Linezolid and other oxazolidi-
nones bind to the 50S ribosomal subunit and inhibit the 
process of protein synthesis. The possible mechanism of 
action of oxazolidinones is binding at the P site of the 
50S ribosomal subunit and inhibition of the initiation 
step of translation [73]. Resistance to oxazolidinones oc-
curs by mutations in the binding site of these antibiotics 
at the 50S subunit. The second generation of oxazolidi-
nones – antibiotic tedizolid, which was approved for use 
in humans in 2014, – has improved potency and broader 
antimicrobial activity. A series of new oxazolidinones 
containing fused heterocyclic rings were synthesized 
and showed higher activity than linezolid against some 
Gram-positive and Gram-negative bacteria [83].
Fujisaki et al. report the synthesis of novel oxazolidi-
none dimers that showed significant activity against 
both Gram-negative and Gram-positive bacteria [84]. 
Interesting approach in search for new antibiotics was 
demonstrated by Gordeev et al. [85] and Hubsch werlen 
et al. [86, 87]. They synthesized new antibiotics by linking 
ciprofloxacin (fluoroquinolone) and oxazolidinone frag-
ments together. The best representative of this class of 
compounds (Fig. 37) showed broad antibacterial activity 
including activity against fluoroquinolone- and linezolid-
resistant bacteria. 
    
 A B  
Fig. 36. Linezolid (A) and tedizolid (B).
Fig. 37. New antibiotic obtained by linking ciprofloxacin and oxa-
zolidinone fragments together.
i. Flouroquinolones
Another important group of antibiotics selectively tar-
gets certain steps of bacterial DNA replication and tran-
scription. Synthetic antibiotics that belong to the flouro-
quinolone class inhibit DNA replication while the natural 
and semisynthetic rifamycins disrupt the transcription 
process.
Fluoroquinolones (e.g. ciprofloxacin and norfloxacin, 
Fig. 38) are considered to be the most successful class of 
synthetic antibiotics. 
Both ciprofloxacin and norfloxacin are synthetic anti-
biotics containing the central quinolone fused ring system.
Fruoroquinolones are broad-spectrum antibiotics. 
They interact with enzymes DNA gyrase and topoi-
somerase IV that leads to the distraction of the DNA 
replication process in the bacterial cell and also pre-
vents the bacterial DNA repair and disrupts the cell 
division process. In the course of the DNA replication 
process, the double stranded DNA is unwound by the 
DNA helicase enzyme. That leads to an under wound 
DNA sector (negative supercoils) on one side of the 
replication fork and super wound DNA sector (positive 
supercoils) on the other side. The main role of DNA gy-
rase is to relieve the DNA supercoiling strand. This is 
achieved by DNA double strand cleavage that leads to 
the relief of both negative and positive supercoiling, 
and then the successful resealing of the DNA double 
strand break. Flouroquinolones interact with the dou-
ble-strand cleaved DNA-enzyme complexes, stabilize 
them, and prevent DNA double-strand resealing [88]. 
The role of enzyme topoisomerase IV is to release the 
two daughter chromosomal circles after the replication 
step that is essential in the process of cell division. This 
is achieved by cutting the DNA double –strand of one of 
the chromosomes, moving the cut site out of the second 
chromosome and the consequent resealing of the cut. 
Fluoroquinolones interact with the complex formed by 
enzyme topoisomerase IV with DNA double-strand cut 
and stabilize it (Fig. 39) [88]. That, in turn, prevents the 
sealing of the double-strand DNA cuts and leads to DNA 
breakage and eventually to bacterial cell death. In spite 
of the wide use of fluoroquinolones in medical practice, 
the detailed molecular mechanism of action of these 
drugs was discovered quite recently. 
Bacterial resistance to this class of antibiotics 
emerged as a result of their widespread use for the treat-
ment of infections in humans. In many cases, these anti-
biotics were misused for the treatment of infections that 
could be treated with other narrow spectrum antimicro-
bials and even for viral infections. 
There are several known mechanisms of resistance to 
quinolones in Staphylococcus aureus. One of them – plas-
mid-mediated – is an active efflux of these antibiotics 
from the bacterial cell by drug pumps. It has been shown 
[89-92] that the NorA efflux pumps are responsible for 
the decreasing of the concentration of some (hydro-
philic) fluoroquinolone drugs in the bacterial cell and 
consequently for the loss of activity of these antibiotics 
in Staphylococcus aureus. According to the recent publi-
cation by Tintino et al. [93], the tannic acid is an efficient 
inhibitor of the NorA efflux pumps in this bacterial strain. 
Thus, they showed that the administration of norfloxacin 
A
     
B
    
Fig. 38. Ciprofloxacin (A) and norfloxacin (B).
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Fig. 39. Drug-stabilized topoisomerase IV – DNA cleavage complex. 
A
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Fig. 40. Prochlorperazine, paroxetine, tannic acid, verapamil, and omeprazole (A, B, C, D, E, correspondingly).
together with tannic acid (Fig. 40C) leads to a significant 
decrease in the minimum inhibitory concentration (MIC) 
for this antibiotic. It was also shown that reserpine is an 
efficient inhibitor of the NorA efflux pumps [94]. Other 
possible inhibitors for these efflux pumps include pro-
chlorperazine, paroxetine, verapamil, and omeprazole 
(Fig. 40 A, B, D, E, correspondingly) [9], although in order 
to achieve significant inhibition a relatively high concen-
tration of these compounds is necessary.
Since active efflux is one of the major mechanisms 
of resistance [95], the search for the new efflux pumps 
inhibitors continues. Coelho et al. [96] showed that ne-
rol (Fig. 41) acting as a drug pump inhibitor can signifi-
cantly increase the activity of norfloxacin against the 
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Staphylococcus aureus strain. According to Felicetti et al. 
[97] 2-(3,4-dimethoxyphenyl)quinoline (Fig. 41) is an ac-
tive NorA pumps inhibitor and can be successfully used 
in combination with ciprofloxacin. 
         
 A B
Fig. 41. Nerol (A) and 2-(3,4-dimethoxyphenyl)quinoline (B).
Other plasmid-mediated resistance mechanisms in-
clude the bacterial production of pentapeptide repeat 
proteins that prevent the drugs from binding to DNA 
gyrase and action of bacterial enzyme aminoglycoside 
acetyltransferase AAC (6’)-Ib-cr leading to the drug in-
activation [98, 99]. Two codon changes in aac (6’)-Ib gene 
directing two substitutions Trp102Arg and Asp179Tyr 
lead to structural changes in aminoglycoside acetyl-
transferase that enable this enzyme to acetylate the cip-
rofloxacin. After the acylation of NH-group of the piper-
azinyl fragment (Fig. 42), the drug shows practically no 
antibacterial activity. 
Fig. 42. Acylation of the piperazinyl fragment of ciprofloxacin.
Obviously, this mechanism of resistance affects only 
those fluoroquinolones that have a piperazinyl ring like 
ciprofloxacin, norfloxacin, etc. Other representatives of 
this class of antibiotics like rufloxacin, perfloxacin, and 
fleroxacin that have an N-methylpiperazinyl fragment 
(Fig. 43) are unaffected by bacterial aminoglycoside acet-
yltransferase AAC(6’)-Ib-cr [99].
        
 A B
C
Fig. 43. Rufloxacin (A), perfloxacin (B), and fleroxacin (C).
In order to overcome the bacterial resistance, a 
search for the new fluoroquinolone antibiotics is ongo-
ing. According to Abu-Qatouseh et al. [100], a number of 
8-nitrofluоroquinolones are active against some strains 
of Helicobacter pylori. Some of these compounds have 
shown synergetic effects when combined with metroni-
dazole. Compounds from other chemical classes are also 
considered as topoisomerase IV inhibitors. A new gyrase 
inhibitor spiropyrimidinetrione AZD0914 (Fig.  44) was 
developed by AstraZeneca [101]. Another new lead com-
pound for gyrase inhibition (Fig.  44, compound 2) was 
reported by Chan et al. [102].
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Fig. 44. AZD0914 (A) and compound 2 (B).
j. Rifamycins
Rifamycins represent the natural and semisynthetic class 
of antibiotics that target RNA polymerase. Natural rifa-
mycins are produced by Amycolatopsis rifamycinica (pre-
viously known as Amycolatopsis mediterranei) although 
they can also be synthesized in the laboratory. Rifampi-
cin, rifapentine, and rifabutin are examples of semisyn-
thetic rifamycins (Fig. 45).
Semisynthetic drugs of this class (e.g. rifampicin) 
have rather broad-spectrum antibiotic activity. Rifamy-
cins bind to the RNA polymerase in the bacterial cell and 
distract the transcription process – DNA dependent syn-
thesis of mRNA [103]. Interaction of the drug molecule 
with the enzyme leads to the formation of a complex that 
prevents the elongation of the mRNA oligonucleotide 
chain. These drugs are active against the Gram-positive 
and some strains of Gram-negative bacteria. Mutations 
in the bacterial RNA polymerase, which can develop very 
quickly, lead to the strong bacterial resistance to these 
antibiotics. Rifamycin producer Amycolatopsis rifamyci-
nica uses this approach for self-protection. The effect of 
different mutations in this enzyme on antibiotic activity 
of rifamycins was discussed recently [104, 105]. General 
overview of this class of antibiotics with a focus on zwit-
terionic compounds is given in [106]. Since these antibi-
otics are used to treat tuberculosis, there is an ongoing 
search for new active compounds. Thus, Bujnowski et al. 
[107] reviewed the development of new methods for the 
synthesis of novel rifamycins, whereas Czerwonka et al. 
[108] described a new series of these antibiotics contain-
ing L-amino acid esters and showed that some of them 
have antibacterial activity comparable to rifampicin. 
k. Lipopeptides
Lipopeptides are the unique class of antibiotics that tar-
get the bacterial membrane. Bacterial membranes have 
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significantly higher content of anionic phospholipids 
than membranes of eukaryotic cells. That allows for the 
selective targeting of bacterial membranes by antibiotics. 
There are several known active lipopeptide antimicrobi-
als and at least three of them –polymyxin B, polymyxin E 
(colistin) (Fig. 46) [109], and daptomycin (Fig. 47) [109] – 
are or have been in clinical practice.
Polymyxins are natural antibiotics produced by dif-
ferent strains of Paenibacillus polymyxa. Daptomycin is 
also a natural compound isolated from bacteria Strepto-
myces roseosporus, although recently a synthetic method 
for this compound was developed. Daptomycin as well as 
polymyxins is synthesized in bacteria by complexes of 
nonribosomal peptide synthetase enzymes. Polymyxins 
are a mixture of several compounds; the major compo-
nents are shown in Fig. 46.
The action of these antibiotics leads to a drastic 
change in bacterial membrane permeability and even-
tually causes bacterial cell death. Thus, it is believed 
that daptomycin initially interacts with the negatively 
charged bacterial membrane by means of coordination 
through the Ca2+ ions, then its lipophilic ‘tail’ is insert-
ed in the membrane bilayer and the consequent inter-
action with several other daptomycin molecules leads 
to oligomerization, and finally ion channel formation 
(Fig. 48). The formation of an ion channel leads to po-
tassium ions efflux from the bacterial cell, membrane 
depolarization, and eventually bacterial cell death [111]. 
Resistance to daptomycin in several bacterial strains has 
been reported. The mechanism of resistance is related 
to the changes in bacterial membrane – from significant 
decrease to the absence of anionic phospholipids in the 
membrane structure [14]. These changes are connected 
with the loss of cdsA activity that encodes the cdsA en-
zyme involved in synthesis of membrane anionic lipids 
A





Fig. 45. Rifampicin (A), rifapentine (B), and rifabutin (C).
A
   
B
  
Fig. 46. Major components of polymyxin E (colistin) (A) and poly-
myxin B (B) [110].
Fig. 47. Daptomycin.
Fig. 48. The proposed mechanism of action of daptomycin.  
Step I – binding and insertion, step II – oligomerization, step III – 
channel formation and ion efflux.
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[15]. In the absence of a negative charge on the bacterial 
membrane daptomycin cannot interact with it through 
the Ca2+ ions and thereby bacteria become resistant to 
this antibiotic.
The recent developments in search for new macrocy-
clic polypeptide antibiotics including glycopeptides and 
lipopeptides was recently reviewed by Luther et al. [112]. 
In general, antimicrobial peptides (AMPs) are getting 
more and more attention as novel promising therapeutic 
agents against antibiotic resistant bacteria [113-115].
CONCLUSION
In conclusion, we can summarize that the general meth-
ods to overcome bacterial resistance are:
1. Discovery of new antibiotics that are active against 
drug resistant bacteria due to:
a. New or improved mechanism of action;
b. New physicochemical properties that makes it im-
possible for bacterial drug efflux pumps to recog-
nize them and to remove them from bacterial cell;
c. Ability to withstand the action of bacterial deacti-
vating enzymes;
d. Ability to bind to the modified target in bacteria 
[41-43, 116-119].
2. Synthesis of new antibiotics with dual or triple mech-
anism of action by the introduction of new functional 
groups in the molecule of the antibiotic [48, 120, 121] 
in order to restore the activity of the drug against the 
resistant bacteria.
3. Synthesis of new dual action antibiotics by linking 
two different antibiotic molecules [85-87, 122]. That 
makes it much more difficult for bacteria to develop 
resistance to these drugs.
4. Administration of antibiotics together with adjuvants 
that help to overcome bacterial resistance [28, 29, 
123, 124]
a. By blocking the action of bacterial drug efflux 
pumps;
b. By blocking the action of bacterial enzymes that 
deactivate the antibiotic;
5. Simultaneous administration of two antibiotics with 
different mechanisms of action [49, 58].
6. Simultaneous administration of two antibiotics with a 
synergetic effect.
New antibiotics that are in the late stages of clinical 
development were recently reviewed by Fernandes et al. 
[125]. 
It should be mentioned that there are a number of 
new approaches in the development of antibiotics active 
against the drug resistant bacteria e.g. development of 
pleuromutilins, quorum-sensing inhibitors, FabI-inhib-
itors, peptidomimetics, inhibitors of bacterial virulence 
etc.
These are definitely very important and promising ar-
eas of research, although no approved antibiotics for use 
in humans (except retapamulin approved for topical use) 
have been discovered so far. 
The rapid spread of antibiotic resistance in bacteria 
makes it necessary to intensify the development of new 
antibiotics and expand the search for new methods to 
fight bacterial resistance. Over the course of these re-
search efforts, scientists are gaining a better understand-
ing of the mechanisms of antibiotic action, the mecha-
nisms of bacterial resistance, and the key biochemical 
processes of the bacterial life cycle. On the other hand, 
new targets for antibiotics in bacteria are being disco-
vered [126].
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